{"id":"NCT00964795","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)","officialTitle":"An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2009-08-25","resultsPosted":"2015-03-23","lastUpdate":"2015-03-23"},"enrollment":323,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Intravitreal Aflibercept Injection 2mg","otherNames":["IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye"]}],"arms":[{"label":"Open-label Intravitreal Aflibercept Injection","type":"EXPERIMENTAL"}],"summary":"The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.","primaryOutcome":{"measure":"Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD","timeFrame":"Baseline (day 1) through end of treatment (Week 180)","effectByArm":[{"arm":"Open-label Intravitreal Aflibercept Injection","deltaMin":290,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":124,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":105,"n":323},"commonTop":["Retinal Haemorrhage","Retinal Haemorrhage","Age-Related Macular Degeneration","Conjunctival Haemorrhage","Hypertension"]}}